In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Myasthenia gravis occurs when the immune system has an abnormal response and produces a type of harmful antibody. These antibodies target and attack receptors called anti-AChR receptors in the ...

Argenx only recently scored FDA approval for its intravenous anti-neonatal FC receptor (FcRn) antibody Vyvgart for generalised myasthenia gravis (gMG), but is already looking to defend its ...

The findings were presented at the Myasthenia Gravis Foundation of America (MGFA ... binding site on the neonatal Fc receptor ...

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...

Welcome, everyone. I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue ...

Sanofi's decision to end development of the drug in myasthenia gravis may lie in the changing landscape of therapies for the disease, including the approval of Argenx' neonatal FC receptor (FcRn ...

Myasthenia gravis (MG) is a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. For most people with MG, the disease is characterized by the presence of antibodies against ...

Severe myasthenia gravis, a rare disease ... "Vyvgart" is an autoimmune disease treatment that targets the neonatal Fc receptor (FcRn), which acts as an immunoglobulin (IgG) defense receptor.